Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis

@article{Ahmed2018BeclabuvirIC,
  title={Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis},
  author={Ali Mahmoud Ahmed and Mohamed Fahmy Doheim and Omar Mohamed Mattar and Nourin Ali Sherif and Duy Hieu Truong and Pham Thi Le Hoa and Kenji Hirayama and Nguyen Tien Huy},
  journal={Journal of Medical Virology},
  year={2018},
  volume={90},
  pages={907 - 918}
}
Daclatasvir, asunaprevir (ASV), and beclabuvir (BCV) are direct‐acting antivirals (DAAs) for patients with hepatitis C virus genotype 1 infection. This systematic review and meta‐analysis investigating the efficacy and safety of this three‐drug combination in HCV genotype 1 infection. Eleven electronic search engines were searched for relevant publications. Studies were screened for eligibility and data was extracted. The outcomes were pooled as event rate and risk ratio (RR). The protocol was… 
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C
TLDR
DCV-TRIO is neither pangenotypic nor potent enough against GT-1a, regardless of the presence or absence of cirrhosis, and this co-formulation might still have a place in the treatment of non-cirrhotic patients infected withGT-1b provided that massive access to treatment is facilitated.
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C
TLDR
This review focuses on the pharmacokinetics, efficacy, tolerability and safety profile of DCV-TRIO, a twice-daily fixed-dose combination of daclatasvir, asunaprevir and beclabuvir approved in Japan for the treatment of genotype 1 HCV infection.
The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
TLDR
It is established that a chronic HCV infection could be cured with small molecule therapy in the absence of immune stimulation, setting the stage for approval of this regimen for the treatment of GT-1b-infected subjects by the Japanese health authorities on July 4, 2014.
The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)
TLDR
The discovery of asunaprevir gave a dose-dependent reduction in plasma viral RNA following oral administration to HCV-infected patients without the burden of the cardiac events that had been observed with 30.
Beclabuvir can Inhibit the RNA-dependent RNA Polymerase of Newly Emerged Novel Coronavirus (SARS-CoV-2)
TLDR
Results suggest beclabuvir may serve as an anti-SARS-CoV-2 drug and suggest the RNA-directed 5'-3' polymerase activity exists within 549th to 776th amino acid residues of RdRpSARS -CoV, the enzyme essential for viral RNA synthesis.
Palladium(0)-Catalyzed Carbonylative Synthesis of N-Acylsulfonamides via Regioselective Acylation.
TLDR
This study further investigated the possibility of labeling N-acylsulfonamides with carbon-11 to facilitate biological evaluation and in vivo studies with positron emission tomography, making it a highly attractive method for the preparation of this important class of compounds.
The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
TLDR
The privileged structures used for the development of antiviral agents are discussed, which typically exhibit good drug- like properties, thus assuring more drug-like properties of modified compound.
Dioxygen-Triggered Oxo-Sulfonylation of Hydrazones.
TLDR
The present C-O and N-S bond-forming difunctionalization strategy affords diversely functionalized N-acylsulfonamides in good yield and suggests a radical mechanistic pathway of the present reaction.
...
1
2
...

References

SHOWING 1-10 OF 74 REFERENCES
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection
TLDR
DCV-TRIO and DUAL exhibited comparable safety profiles and SVR12 was achieved by 96 % of Japanese patients with HCV genotype 1 infection after 12 weeks of treatment with the DCV- TRIO regimen.
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
TLDR
Interferon‐free, ribavirin‐free all‐oral therapy with daclatasvir and asunaprevir for 24 weeks is well tolerated and can achieve a high rate of SVR in patients with HCV genotype 1b who were ineligible, intolerant, or had not responded to prior interferon-based therapy.
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
TLDR
Patients with chronic HCV genotype 1 infection and cirrhosis who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin achieved high rates of sustained virologic response at posttreatment week 12 (SVR12).
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
TLDR
In this open-label, nonrandomized, uncontrolled study, a high rate of SVR12 was achieved in treatment-naive and treatment-experienced noncirrhotic patients with chronic HCV genotype 1 infection who received 12 weeks of treatment with the oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir.
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
TLDR
Following DCV + ASV treatment, the SVR12 rates in GT-1b patients without baseline NS5A-L31F/I/M/V and/or NS5a-Y93H polymorphisms were very high, with similarly high rates observed among treatment-naïve and interferon-experienced patients and those with high baseline HCV RNA.
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
TLDR
Simeprevir + sofosbuvir for 12 weeks achieved superiority in SVR12 rates versus the historical control in treatment‐naive and treatment‐experienced HCV GT1‐infected patients with cirrhosis and was generally safe and well tolerated.
Pooled Analysis of HCV Genotype 1 Resistance-Associated Substitutions in NS5A, NS3 and NS5B pre- and Post-Treatment with 12 Weeks of Daclatasvir, Asunaprevir and Beclabuvir
TLDR
DCV+ASV+BCV±RBV was highly efficacious in HCV GT-1 infection, including HCVGT-1b with NS5A RAS, and the fitness of treatment-emergent RAS post-treatment was NS5 a > NS3 > NS5B; NS3 and NS5 B RAS were generally replaced by wild-type sequence within 48 weeks.
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
TLDR
In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection.
...
1
2
3
4
5
...